{
    "info": {
        "nct_id": "NCT03374488",
        "official_title": "A Phase 3 Randomized, Double-Blind Clinical Study of Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo as a Treatment for Recurrent or Progressive Metastatic Urothelial Carcinoma in Patients Who Have Failed a First-Line Platinum-containing Chemotherapy Regimen for Advanced/Metastatic Disease (KEYNOTE-698/ECHO-303)",
        "inclusion_criteria": "* Histologically-confirmed diagnosis of urothelial carcinoma of the renal pelvis, ureter, bladder, or urethra, that is transitional cell, or mixed transitional/non-transitional (predominantly transitional) cell type.\n* Progression or recurrence of urothelial carcinoma following one prior platinum containing chemotherapy regimen for metastatic or unresectable locally advanced disease. A participant who receives a neoadjuvant or adjuvant platinum-containing regimen following cystectomy for localized muscle-invasive urothelial carcinoma is acceptable (without further systemic treatment), if recurrence/progression occurs ≤ 12 months following completion of therapy.\n* Measurable disease based on RECIST v1.1.\n* Have provided an archival tumor tissue sample or newly obtained core or excisional biopsy of a tumor lesion not previously irradiated for PD-L1 analysis.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Adequate organ function per protocol-defined criteria.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Urothelial carcinoma that is suitable for local therapy with curative intent.\n* History or presence of an abnormal electrocardiogram (ECG) that, in the investigator's opinion, is clinically meaningful.\n* Known additional malignancy that is progressing or has required active treatment within the past 3 years.\n* Known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable, ie, without evidence of progression for at least 4 weeks by repeat imaging.\n* Active autoimmune disease that has required systemic treatment in past 2 years.\n* Known history of human immunodeficiency virus (HIV) infection. HIV testing is not required unless mandated by local health authority.\n* Known history of or is positive for active hepatitis B (HBsAg reactive) or has active hepatitis C (HCV RNA). Note: Testing must be performed to determine eligibility.\n* Use of protocol-defined prior/concomitant therapy.",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Histologically-confirmed diagnosis of urothelial carcinoma of the renal pelvis, ureter, bladder, or urethra, that is transitional cell, or mixed transitional/non-transitional (predominantly transitional) cell type.",
            "criterions": [
                {
                    "exact_snippets": "Histologically-confirmed diagnosis of urothelial carcinoma",
                    "criterion": "urothelial carcinoma diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": "histologically-confirmed"
                        }
                    ]
                },
                {
                    "exact_snippets": "urothelial carcinoma of the renal pelvis, ureter, bladder, or urethra",
                    "criterion": "primary tumor site",
                    "requirements": [
                        {
                            "requirement_type": "anatomic location",
                            "expected_value": [
                                "renal pelvis",
                                "ureter",
                                "bladder",
                                "urethra"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "that is transitional cell, or mixed transitional/non-transitional (predominantly transitional) cell type",
                    "criterion": "tumor cell type",
                    "requirements": [
                        {
                            "requirement_type": "cell type",
                            "expected_value": [
                                "transitional cell",
                                "mixed transitional/non-transitional (predominantly transitional)"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Measurable disease based on RECIST v1.1.",
            "criterions": [
                {
                    "exact_snippets": "Measurable disease based on RECIST v1.1.",
                    "criterion": "disease",
                    "requirements": [
                        {
                            "requirement_type": "measurability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "assessment_criteria",
                            "expected_value": "RECIST v1.1"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Have provided an archival tumor tissue sample or newly obtained core or excisional biopsy of a tumor lesion not previously irradiated for PD-L1 analysis.",
            "criterions": [
                {
                    "exact_snippets": "Have provided an archival tumor tissue sample or newly obtained core or excisional biopsy of a tumor lesion",
                    "criterion": "tumor tissue sample",
                    "requirements": [
                        {
                            "requirement_type": "availability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "source",
                            "expected_value": [
                                "archival",
                                "newly obtained core biopsy",
                                "newly obtained excisional biopsy"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "tumor lesion not previously irradiated",
                    "criterion": "tumor lesion irradiation status",
                    "requirements": [
                        {
                            "requirement_type": "irradiation status",
                            "expected_value": "not previously irradiated"
                        }
                    ]
                },
                {
                    "exact_snippets": "for PD-L1 analysis",
                    "criterion": "PD-L1 analysis suitability",
                    "requirements": [
                        {
                            "requirement_type": "suitability for analysis",
                            "expected_value": "PD-L1"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Progression or recurrence of urothelial carcinoma following one prior platinum containing chemotherapy regimen for metastatic or unresectable locally advanced disease. A participant who receives a neoadjuvant or adjuvant platinum-containing regimen following cystectomy for localized muscle-invasive urothelial carcinoma is acceptable (without further systemic treatment), if recurrence/progression occurs ≤ 12 months following completion of therapy.",
            "criterions": [
                {
                    "exact_snippets": "Progression or recurrence of urothelial carcinoma",
                    "criterion": "urothelial carcinoma",
                    "requirements": [
                        {
                            "requirement_type": "disease status",
                            "expected_value": [
                                "progression",
                                "recurrence"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "following one prior platinum containing chemotherapy regimen for metastatic or unresectable locally advanced disease",
                    "criterion": "prior platinum-containing chemotherapy regimen",
                    "requirements": [
                        {
                            "requirement_type": "number of regimens",
                            "expected_value": {
                                "operator": "=",
                                "value": 1,
                                "unit": "regimen"
                            }
                        },
                        {
                            "requirement_type": "indication",
                            "expected_value": [
                                "metastatic disease",
                                "unresectable locally advanced disease"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "A participant who receives a neoadjuvant or adjuvant platinum-containing regimen following cystectomy for localized muscle-invasive urothelial carcinoma is acceptable (without further systemic treatment), if recurrence/progression occurs ≤ 12 months following completion of therapy.",
                    "criterion": "neoadjuvant or adjuvant platinum-containing regimen after cystectomy for localized muscle-invasive urothelial carcinoma",
                    "requirements": [
                        {
                            "requirement_type": "treatment type",
                            "expected_value": [
                                "neoadjuvant",
                                "adjuvant"
                            ]
                        },
                        {
                            "requirement_type": "platinum-containing regimen",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "post-cystectomy",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "further systemic treatment",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "recurrence/progression timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 12,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Adequate organ function per protocol-defined criteria.",
            "criterions": [
                {
                    "exact_snippets": "Adequate organ function per protocol-defined criteria",
                    "criterion": "organ function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "per protocol-defined criteria",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Known history of human immunodeficiency virus (HIV) infection. HIV testing is not required unless mandated by local health authority.",
            "criterions": [
                {
                    "exact_snippets": "Known history of human immunodeficiency virus (HIV) infection",
                    "criterion": "HIV infection",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known additional malignancy that is progressing or has required active treatment within the past 3 years.",
            "criterions": [
                {
                    "exact_snippets": "Known additional malignancy that is progressing",
                    "criterion": "additional malignancy",
                    "requirements": [
                        {
                            "requirement_type": "progression status",
                            "expected_value": "progressing"
                        }
                    ]
                },
                {
                    "exact_snippets": "Known additional malignancy that ... has required active treatment within the past 3 years",
                    "criterion": "additional malignancy",
                    "requirements": [
                        {
                            "requirement_type": "active treatment requirement",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "active treatment time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Urothelial carcinoma that is suitable for local therapy with curative intent.",
            "criterions": [
                {
                    "exact_snippets": "Urothelial carcinoma",
                    "criterion": "urothelial carcinoma",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "suitable for local therapy with curative intent",
                    "criterion": "suitability for local therapy with curative intent",
                    "requirements": [
                        {
                            "requirement_type": "suitability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Use of protocol-defined prior/concomitant therapy.",
            "criterions": [
                {
                    "exact_snippets": "Use of protocol-defined prior/concomitant therapy",
                    "criterion": "protocol-defined prior/concomitant therapy",
                    "requirements": [
                        {
                            "requirement_type": "use",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known history of or is positive for active hepatitis B (HBsAg reactive) or has active hepatitis C (HCV RNA). Note: Testing must be performed to determine eligibility.",
            "criterions": [
                {
                    "exact_snippets": "Known history of ... active hepatitis B (HBsAg reactive)",
                    "criterion": "hepatitis B infection",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "is positive for active hepatitis B (HBsAg reactive)",
                    "criterion": "hepatitis B infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "HBsAg",
                            "expected_value": "reactive"
                        }
                    ]
                },
                {
                    "exact_snippets": "has active hepatitis C (HCV RNA)",
                    "criterion": "hepatitis C infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "HCV RNA",
                            "expected_value": "positive"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active autoimmune disease that has required systemic treatment in past 2 years.",
            "criterions": [
                {
                    "exact_snippets": "Active autoimmune disease that has required systemic treatment in past 2 years.",
                    "criterion": "autoimmune disease",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "systemic treatment requirement",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "systemic treatment timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History or presence of an abnormal electrocardiogram (ECG) that, in the investigator's opinion, is clinically meaningful.",
            "criterions": [
                {
                    "exact_snippets": "History or presence of an abnormal electrocardiogram (ECG)",
                    "criterion": "electrocardiogram (ECG) abnormality",
                    "requirements": [
                        {
                            "requirement_type": "history or presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "that, in the investigator's opinion, is clinically meaningful",
                    "criterion": "clinical meaningfulness of ECG abnormality",
                    "requirements": [
                        {
                            "requirement_type": "clinical meaningfulness (per investigator)",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable, ie, without evidence of progression for at least 4 weeks by repeat imaging.",
            "criterions": [
                {
                    "exact_snippets": "Known active central nervous system (CNS) metastases",
                    "criterion": "central nervous system (CNS) metastases",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "carcinomatous meningitis",
                    "criterion": "carcinomatous meningitis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Participants with previously treated brain metastases may participate provided they are radiologically stable, ie, without evidence of progression for at least 4 weeks by repeat imaging.",
                    "criterion": "previously treated brain metastases",
                    "requirements": [
                        {
                            "requirement_type": "treatment status",
                            "expected_value": "previously treated"
                        },
                        {
                            "requirement_type": "radiological stability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "progression-free duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}